Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358858 | 0.93 | TLR2 (0.46) | TLR2PTPN1MDM2 | |
| SCHEMBL29355954 | 0.92 | PTPN1 (0.48) | TLR2PTPN1MDM2 | |
| SCHEMBL24235686 | 0.90 | PTPN1 (0.54) | PTPN1MDM2BCHEACHECACNA1F | |
| SCHEMBL18576004 | 0.89 | MDM2 (0.46) | TLR2MDM2 | |
| SCHEMBL29692843 | 0.88 | PTPN1 (0.43) | TLR2PTPN1MDM2 | |
| SCHEMBL16093056 | 0.88 | MDM2 (0.48) | TLR2PTPN1MDM2 | |
| SCHEMBL10078351 | 0.88 | MDM2 (0.48) | TLR2PTPN1MDM2 | |
| SCHEMBL17322760 | 0.87 | TLR2 (0.47) | TLR2PTPN1MDM2 | |
| SCHEMBL12356377 | 0.86 | TLR2 (0.54) | TLR2 | |
| SCHEMBL24235738 | 0.86 | PTPN1 (0.56) | PTPN1MDM2BCHEACHECACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | ENZENE BIOSCIENCES LIMITED (IN) | 2026-04-14 | — | — | US | disclosed |
| US-20220153804-A1 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | ENZENE BIOSCIENCES LIMITED (IN) | 2022-05-19 | — | — | US | disclosed |
| EP-3941936-A2 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | Enzene Biosciences Ltd. (IN) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153804-A1 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | GLP1R, GIPR, GCGR | TLR2 1925/4885PTPN1 330/4885MDM2 3435/4885 |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | GLP1R, GIPR, GCG | TLR2 1915/4885PTPN1 2094/4885MDM2 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.